JP6495430B2 - Bromofenac sodium polymorph and process for producing bromfenac sodium polymorph - Google Patents

Description

Field of Invention

This application is related to US Provisional Patent Application No. 61/25192 filed on Oct. 15, 2009.
No. 5, and British Provisional Patent Application No. 0919757, filed on November 12, 2009.
No. 5 is claimed and the matters disclosed in the specifications of these patent applications are included in the present specification as they are.

The present invention relates to novel polymorphs of bromfenac sodium, new reproducible methods for their production, and pharmaceutical compositions comprising such polymorphs.

Consideration of related technology

Bromfenac sodium (2-amino-3- (4-bromobenzoyl) phenylacetic acid sodium salt, sometimes referred to as sodium 2-amino-3- (4-bromobenzoyl) acetic acid phenyl sesquihydrate, experimental formula _{C 15 H 11 BrNNaO 3 · 1.5H} 2
O) is a non-steroidal anti-inflammatory drug (NSAID) with analgesic action. that is,
Originally marketed as an oral suspension under the trade name DURACT, it withdrew from the US market in 1998 due to drug-induced hepatotoxicity causing acute liver failure. Recently, bromfenac sodium is marketed under the brand name XIBROM as an eye drop. The Food and Drug Administration approved this product for use in ophthalmic surgery in 2005, including post-operative inflammation, reduction of pain after cataract and refractive surgery, and treatment of macular edema after cataract surgery. XIBRO
M eye drops contain 1.035 mg bromfenac sodium, corresponding to 0.9 mg bromfenac free acid per mL of solution provided with a 0.09% sterile topical ophthalmic formulation with pH 8.3.

A review of the literature on bromfenac sodium did not provide any literature regarding its crystal structure or the possibility of different polymorphs. Information on the solid properties of the drug substance is important. For example, different forms may have significantly different solubilities. The handling and stability of the drug substance obviously depends on the solid form.

Polymorphs are defined as “the ability of a compound to crystallize in one or more different crystal species” and different crystal arrangements of the same chemical component are referred to as polymorphs. Polymorphs of the same compound are caused by differences in the internal arrangement of atoms and have different physical properties such as different free energy and thus solubility, chemical stability, melting point, density, flowability, bioavailability and the like.

It has now been found that bromfenac sodium can be produced in three well-defined and consistently reproducible crystalline forms and specific mixtures of these crystalline forms. In addition, a reliable and measurable method has been developed for interconverting these crystal forms. The bromfenac sodium polymorph provided by the present invention is a useful active ingredient in pharmaceutical formulations.

In one aspect of the invention, bromfenac sodium Form I is provided, and is desirably substantially free of other physical forms of bromfenac sodium. This bromfenac sodium polymorph is a highly crystalline consistent polymorph and a stable sesquihydrate. Bromofenac sodium Form I is produced by a process comprising crystallizing or recrystallizing bromfenac sodium from a solvent mixture comprising water, at least one dialkoxyalkane, and at least one non-solvent. May be. The present invention allows bromfenac sodium Form I to be obtained in a high purity form.
In particular, bromfenac sodium Form I with very low levels of residual sodium hydroxide and other reagents (carried over from the synthesis of bromfenac sodium), organic solvents,
Process impurities and bromfenac sodium degradation products may be produced.

In another aspect of the invention, bromfenac sodium form II is provided. Bromfenac sodium Form II is a hydrate of bromfenac sodium containing no more than 1.5 moles of water per mole of bromfenac sodium (eg, about 1 mole of water per mole of bromfenac sodium). .

In yet another aspect of the invention, bromfenac sodium form III is provided. Bromfenac Sodium Form III is a non-hydrous polymorph of bromfenac sodium produced by a process that includes crystallizing or recrystallizing bromfenac sodium from a solvent mixture containing water and at least one alcohol. May be. Another method for preparing bromfenac sodium Form III is to prepare 7- (4-bromobenzoyl) indol-2-one in a mixture of water, at least one alcohol, and at least one aromatic hydrocarbon, Treating with sodium oxide to obtain a bromfenac sodium reaction mixture and mixing at least one non-solvent with the bromfenac sodium reaction mixture.

A mixture comprising bromfenac sodium form I and bromfenac sodium form II is also provided by the present invention. Such a mixture crystallizes or recrystallizes bromfenac sodium from a solvent mixture comprising water, at least one dialkoxyalkane and at least one non-solvent to yield an initial solid and vacuum Below,
It may be produced by drying the initial solid.

A method of converting bromfenac sodium form I to bromfenac sodium form II is also provided by the present invention and under vacuum, bromfenac sodium form I
Including drying.

The present invention also provides a substance selected from bromfenac sodium form I, bromfenac sodium form II, or a mixture of bromfenac sodium form I and bromfenac sodium form II to bromfenac sodium form III. A method of conversion is provided, comprising crystallizing or recrystallizing the material from a solvent mixture comprising water and at least one alcohol.

In another embodiment of the invention, bromfenac sodium form II is converted to bromfenac sodium form I by a process comprising hydrating bromfenac sodium form II.

Further provided by the present invention is a process for converting bromfenac sodium Form III to bromfenac sodium Form I. In this method, bromfenac sodium form III is crystallized or recrystallized from a solvent mixture containing at least one non-solvent such as water, at least one dialkoxyalkane, and a dialkyl ether to produce bromfenac. Producing an intermediate product comprising no more than 1.5 moles of water per mole of sodium and hydrating the intermediate product.

In yet another aspect of the present invention, bromfenac sodium form I comprises crystallization or recrystallization of bromfenac sodium form I from a solvent mixture comprising water and at least one alcohol. May be converted to bromfenac sodium form III.

Further provided by the present invention is a process for converting bromfenac sodium Form III to bromfenac sodium Form II. This method crystallizes or recrystallizes bromfenac sodium Form III from a solvent mixture comprising at least one non-solvent such as water, at least one dialkoxyalkane, and dialkyl ether to obtain an intermediate product. And drying the intermediate product in a vacuum.

FIG. 1 is a representative powder X-ray diffraction (XRPD) pattern of bromfenac sodium Form I according to the present invention. FIG. 2 is an FT-IR spectrum of a representative sample of bromfenac sodium Form I according to the present invention. FIG. 3 is a representative powder X-ray diffraction (XRPD) pattern of bromfenac sodium Form III according to the present invention. FIG. 4 is an FT-IR spectrum of a representative sample of bromfenac sodium Form III according to the present invention. FIG. 5 is a powder X-ray diffraction (XRPD) pattern of a mixture of bromfenac sodium Form I and bromfenac sodium Form II according to the present invention. FIG. 6 is a predicted XRPD pattern for bromfenac sodium Form II according to the present invention. FIG. 7 illustrates in graphical form one polymorphic interconversion that can be realized through the present invention.

Detailed Description of Certain Embodiments of the Invention

For the production of the bromfenac sodium polymorph that is the subject of the present invention, the bromfenac sodium used as starting material may be synthesized using any method known in the art. For example, bromfenac sodium is a product of Walsh et al, Jour
nal of Medicinal Chemistry, No. 27, page 1379-
For reference, the descriptions of these documents are included as part of the present specification and may be manufactured as shown in page 1388 (1984) or US Pat. No. 4,683,242 (Example 74).

Bromfenac sodium Form I is a highly crystalline polymorph of bromfenac provided by the present invention and is a stable sesquihydrate. FIG. 1 is a representative powder X-ray diffraction (XRPD) pattern of bromfenac sodium Form I. Table A lists the d-spacing /% intensity pattern unique to bromfenac sodium Form I (no peaks with a relative intensity of <2.0% are listed). Bromfenac sodium form I
Powder X-ray diffraction patterns of about 4.4, 8.8, 9.4, 12.1, 15.2, 15.9.
17.6, 18.2, 18.8, 20.2, 21.2, 24.7, 28.4, and 32.
. It may have a main peak represented as 2-θ at 4 °. FIG. 2 shows the FT-IR spectrum of a representative sample of bromfenac sodium Form I. In one embodiment, bromfenac sodium Form I is purified and separated so that it is substantially free of other physical forms of bromfenac sodium. “Substantially free” in the context of the present invention means that the powder X-ray diffraction pattern does not show any visible peaks associated with other bromfenac sodium polymorphs.

The present invention allows the production of bromfenac sodium Form I not only substantially free of other physical forms of bromfenac sodium but also having a very high level of chemical purity. That is, bromfenac sodium Form I produced according to the present invention is a process impurity (ie, impurities structurally related to bromfenac sodium and precursors of bromfenac sodium, etc.) that are carried forward during the synthesis process. Impurities produced or produced), degradation products of bromfenac sodium, and substances not related to bromfenac sodium, such as residual solvents, metals or reagents carried over from the production process. For example, in one embodiment, bromfenac sodium Form I product has an AUC of greater than or equal to 0.15% of impurities or bromfenac sodium degradation products in any process as measured by high pressure liquid chromatography (in another method, , AUC 0.10% or less). As another example, the present invention provides that bromfenac sodium Form I is substantially free of residual sodium hydroxide as evidenced by the relatively low pH when dissolved in water. Allows the production of sodium Form I. It has been found that a high level of residual sodium hydroxide increases the hygroscopicity of bromfenac sodium Form I product. (That is, it shows a great tendency to absorb more than 1.5 moles of water per mole of bromfenac sodium.) Desirably, the pH of such a solution is 11 or less, or more desirably 10 pH. .6 or less. In another embodiment, bromfenac sodium Form I has a total of 200 ppm or less, as measured by gas chromatography,
Alternatively, an organic solvent of 150 ppm or less may be included. In yet another aspect, bromfenac sodium Form I comprises a total of 100 ppm or less of aluminum, boron, and manganese, as measured by radio frequency inductively coupled plasma optical emission spectrometry (ICP-OES),
And / or 30 ppm or less of each of these elements.
Table A.

Bromfenac sodium Form I is produced by a process comprising crystallizing or recrystallizing bromfenac sodium from a solvent mixture comprising water, at least one dialkoxyalkane, and at least one non-solvent. May be. Bromofenac sodium may be an initial or crude reaction product obtained by synthesizing bromfenac sodium from a suitable precursor, such as hydrolysis of the corresponding indolone. The starting material for bromfenac sodium is also eg bromfenac sodium form III
It may be. In addition to producing bromfenac sodium Form I crystals substantially free of other bromfenac sodium polymorphs, such a crystallization and recrystallization process can be used in the bromfenac sodium starting material. (Unreacted or residual reagents, by-products, etc.), providing further advantages to facilitate removal or reduction of other impurities. For example, the bromfenac sodium starting material may be a sample of bromfenac sodium form I contaminated with chemical impurities and / or small amounts of one or more other bromfenac polymorphs, and recrystallization may occur in this sample. Effective to improve chemical and / or polymorph purity.

In one embodiment of the invention, crystallization or recrystallization is performed by dissolving the starting bromfenac sodium in a mixture of water and dialkoxyalkane to produce an initial solution. This solvent mixture may be heated, for example, to a temperature of about 40 ° C. to about 90 ° C. to facilitate dissolution of bromfenac sodium. Next, one or more non-solvents are added to the initial solution, and the resulting mixture is cooled (eg, with or without stirring), thereby forming the desired bromfenac sodium Form I crystals. It is possible to precipitate out of solution. For example, the mixture may be cooled to a temperature of about −10 ° C. to about 20 ° C. Bromofenac sodium Form I seeds may be added to accelerate or accelerate the crystallization process. An initial sample of bromfenac sodium
If contaminated with poorly soluble impurities, it is desirable to filter the initial solution and / or its mixture following the addition of non-solvent (before cooling) to remove such impurities. Bromfenac sodium Form I crystals can be filtered, decanted, or centrifuged,
It may be collected and separated from the mother liquor by any conventional separation technique. Then, if further desired, further purification or processing procedures such as washing and / or drying are imposed. The separated mother liquor may be further processed to recover additional bromfenac sodium Form I crystals and / or purified solvent for reuse in a crystallization or recrystallization procedure. These techniques may be immediately applied for use in connection with other crystallization / recrystallization process practices presented herein for other bromfenac sodium polymorphs.

Suitable dialkyalkanes are 1,2-dimethoxyethane, 1,2-dimethoxypropane, 2,2-dimethoxypropane, diethoxymethane, 1,1-diethoxyethane, 1,2
Including, but not limited to, hydrocarbons substituted with two or more C ₁ -C ₄ alkoxy groups, such as -diethoxyethane, and mixtures thereof. As used herein, the term non-solvent means that the desired product (ie, crystallized or recrystallized product) is insoluble or
It means a solvent that is essentially insoluble. Thus, the function of the non-solvent is to reduce the solubility of the product in the solvent mixture and thereby improve the yield of precipitated crystals recovered.
Suitable non-solvents include dialkyl ethers, diethyl ether, dipropyl ether, diisopropyl ether, tert- butyl methyl ether, sec- butyl methyl ether, especially a dialkyl ether of _C 4 _{-C 10,} and mixtures thereof. In one particularly advantageous embodiment, the solvent mixture is water, 1,2-dimethoxyethane, and t
erf-butyl methyl ether.

If the bromfenac sodium starting material is contaminated with an undesirably high level of residual sodium (such as sodium hydroxide) carried over from the indolone hydrolysis process used to produce the bromfenac sodium starting material The following method may be continued to obtain bromfenac sodium Form I, which is free or substantially free of residual sodium contaminants. Bromofenac sodium starting material at an effective temperature (
55 to 80 ° C., etc.), an aqueous dialkoxyalkane mixture (such as 10-20% v / v water (3-8 mL / g bromofenac sodium) in 1,2-dimethoxyethane),
A solution is formed (the mixture may be degassed by bubbling an inlet gas such as nitrogen through the mixture before heating). The solution is then allowed to settle until an aqueous layer forms (the aqueous layer will contain at least a portion of residual sodium contaminants.
). The organic layer is separated from the aqueous layer. While the organic layer is still warm (to avoid premature crystallization of bromfenac sodium), filtration may be performed to remove insoluble impurities. The organic layer is then concentrated (such as under vacuum) to form a wet slurry. This wet slurry is then mixed with a non-solvent such as tert-butyl methyl ether. Thus, crystalline, purified bromfenac sodium Form I is recovered by filtration, and washed (eg, with a non-solvent addition) and dried (less than 1.5 moles of water per mole of sodium bromfenac). (With care to avoid overdrying) as may be present in the final product.

In another aspect of the invention, the bromfenac sodium starting material is 8-12% v in 1,2-dimethoxyethane (10-14 mL / g bromfenacnatrim starting material) at 50-75 ° C. Dissolved in a mixture of / v water to form a solution. This solution was filtered while still warm to remove any insoluble impurities, then 15-25% (8-12 mL / g bromofenac sodium starting material) in tert-butyl methyl ether.
It may be mixed with a mixed solution of v / v 1,2-dimethoxyethane. The resulting liquid mixture is cooled to a temperature of 0 ° C. to 15 ° C. for several hours or more (4 hours to 8 hours, etc.) to provide bromfenac sodium form I as a highly crystalline product. It may be separated and dried. If necessary (for example, when the drying conditions used to remove the organic solvent from the crystalline product yield less than 1.5 molecules of water per molecule of bromfenac sodium) A hydration reaction of the product may be performed to confirm that the stable sesquihydrate is a single polymorph present.

The hydration reaction may be carried out by exposing the product to water, especially water vapor. For example, the product may be placed in a sealed chamber under vacuum and water vapor (e.g.,
(In the form of moist air or moist nitrogen) may be bleed in a closed chamber. Alternatively, the product may be exposed to a humid atmosphere at approximately atmospheric pressure in a closed chamber containing a source of liquid water.

If so desired, the method shown above for producing bromfenac sodium Form I is adapted to provide a product which is a mixture of bromfenac sodium Form I and bromfenac sodium Form II, and It may be changed. Bromfenac sodium form II, ie contains 1 water molecule per molecule of bromfenac sodium,
A polymorph seen as the monohydrate of bromfenac sodium and about 11.3,
14.4, 16.5, 17.3, 18.5, 19.4, 20.7, 21.0, 22.7,
Characterized by a powder X-ray diffraction pattern with a major peak represented as 2-θ at 29.0, 31.8, 34.1 and 36.1 °. In the crystallization process as shown above, under vacuum, the first obtained crystal product is dried to remove some water of the hydration reaction from the sesquihydrate and as evidenced by XRPD Results in the formation of Form II polymorphs. Vacuum drying conditions may be adjusted to change the polymorph content of Form II of the resulting product. For example, higher drying temperatures, lower pressures, and increased drying times generally increase all the amount of bromfenac sodium form II present. Such parameters are selected to provide bromfenac sodium form II in substantially pure form (substantially free of any bromfenac sodium form I or any other polymorph). It is thought that it may be. However, since bromfenac sodium form II is not stable, it is protected from atmospheric moisture, or other water sources, from hydration reactions and conversion to another polymorph, such as bromfenac sodium form I, You should protect it.

In another aspect of the present invention, bromfenac sodium Form I is bromfenac sodium Form III, water, and dialkoxyalkane (1) at a time and temperature effective to form an organic layer and an aqueous layer. May be prepared from bromfenac sodium form III by a process comprising heating (desirably after degassing) a mixture of 2 dimethoxyethane and the like. Following separation of the aqueous layer, and optionally filtration, the organic layer is concentrated with one or more non-solvents (such as dialkyl ethers) effective to cause precipitation / crystallization of the desired bromfenac sodium Form I. And may be mixed. Therefore, bromfenac sodium Form I obtained in solid form may be separated from the mother liquor, washed (with non-solvent, etc.) and dried by filtration, decantation, centrifugation, etc., if desired (as described above). As indicated, excessively severe drying conditions should be avoided if substantially pure bromfenac sodium Form I is desired.)

Bromfenac sodium Form III is a crystalline polymorph of bromfenac provided by the present invention that does not contain any water of hydration reaction. The solubility in water is significantly lower than that observed for bromfenac sodium Form I or other hydrates of bromfenac sodium. Bromfenac sodium Form III was found to be stable and showed little tendency to adsorb water (17 hours, 30 ° C. to 35 ° C. in a vacuum oven (5 mm Hg) with wet nitrogen “ The moisture content of the sample subjected to the “hydration reaction” condition did not change.) FIG. 3 is a representative powder X-ray diffraction (XRPD) pattern of bromfenac sodium Form III. Table B lists the d-spacing /% intensity pattern unique to bromfenac sodium Form III. The powder X-ray diffraction pattern of bromfenac sodium Form III is about 12.2, 12.4, 14.1, 17.8, 19.
It may have a major peak represented as 2-θ at 6, 21.6, 22.4, 24.0, 26.3, and 28.1 °. FIG. 4 shows FT-IR diffraction of a representative sample of bromfenac sodium Form III. In one embodiment, bromfenac sodium Form III is purified and separated such that it is substantially free of other physical forms of bromfenac sodium.
Table B.

Bromfenac sodium Form III may be produced by a process comprising crystallizing and / or recrystallizing bromfenac sodium from a solvent mixture comprising water and at least one alcohol. This result was surprising in view of the fact that water is present in the solvent mixture and is expected to be incorporated into the bromfenac sodium crystals formed during crystallization / recrystallization. The at least one alcohol may comprise one or more C ₁ -C ₄ alcohols, especially at least one of ethanol or 2-propanol. Water and 2-propanol (including about 2% to about 8% v / v water, etc.)
A solvent mixture comprising, in substantially pure form, bromfenac sodium form II
It has been found that it is particularly suitable for use as a crystallization or recrystallization solvent to obtain I polymorphs. For example, the bromfenac sodium starting material may be bromfenac sodium Form I, bromfenac sodium Form II, and / or a mixture of Form I and Form II polymorphs.

Another method for producing bromfenac sodium Form III uses a base containing sodium, such as sodium hydroxide, in a solvent comprising water, at least one alcohol, and at least one aromatic hydrocarbon. -(4-Bromobenzoyl) indole-2-
Treating the ON to obtain a reaction mixture that is mixed with at least one non-solvent. A temperature effective to convert indol-2-one to the corresponding sodium salt (eg, about 5
It is desirable to heat the reaction mixture before mixing with the non-solvent at 0 ° C. to about 90 ° C.) and for a time (eg, about 3 hours to about 25 hours). Following such heating, the reaction mixture is
Some cooling may occur before the non-solvent is added (eg, from about 20 ° C. to about 40 ° C.).
The addition of a non-solvent results in crystallization or precipitation of the desired bromfenac sodium form III in a solid, which is then separated from the mother liquor by filtration, centrifugation, decantation or other separation methods. , Washed with a suitable solvent (such as tert-butyl methyl ether, non-solvent) and dried. Suitable alcohols are methanol, ethanol, 1-
Including propanol, 2-propanol, 1-butanol, 2-butanol, tert-butanol, and the like, C ₁ -C ₄ alcohols, and mixtures thereof. Suitable aromatic hydrocarbons include aromatic ring by one, and includes C ₁ -C ₄ alkyl group or a halogen or the like, aromatic hydrocarbons optionally substituted with one or more substituents other than hydrogen. Toluene and xylene are examples of useful aromatic hydrocarbons. Suitable non-solvents include but are not limited to alkyl ethers such as tert-butyl methyl ether. The amount of non-solvent desirably used is sufficient to cause precipitation of at least a majority of the bromfenac sodium present in the reaction mixture. In one embodiment of the invention, the solvent and reagent solution (eg, sodium hydroxide solution) is degassed prior to use, such as by bubbling an inlet gas, such as nitrogen, through the solvent or reagent solution.

The present invention further provides a method for converting one polymorph of bromfenac sodium to a different bromfenac polymorph. FIG. 7 shows, in schematic form, some possible interconversions. The particular solvent system described in FIG. 7 is for illustration only and is not intended to be limited to any method. Also, as used herein, the terms “crystallization” (or “crystallization”) and “recrystallization” (or “recrystallization”) refer to a complete solution,
It is intended to include not only the processes that are realized at some point in the process, but also processes in which the material to be crystallized or recrystallized is never completely dissolved at any point in time. That is, this interconversion leaves at least a portion of the material to be converted or processed undissolved (ie, the material / solvent mixture is a solid slurry in a liquid medium rather than a complete solution). May be realized using a method.

As mentioned above, bromfenac sodium Form I is transformed into bromfenac sodium Form II by drying bromfenac sodium Form I under vacuum.
It may be at least partially converted. Further, as described above, bromfenac sodium form II is converted to bromfenac sodium form I by hydrating bromfenac sodium form II.

In addition, bromfenac sodium form I, bromfenac sodium form II,
Or a substance selected from a mixture of bromfenac sodium form I and bromfenac sodium form II crystallizes or recrystallizes the substance from a solvent mixture comprising water and at least one alcohol. May be converted to bromfenac sodium form III. Appropriate alcohol and crystallization / recrystallization conditions are
In general, similar to the alcohol and crystallization / recrystallization conditions described above in connection with the preparation of bromfenac sodium form III from bromfenac sodium.

A method for converting bromfenac sodium Form III to bromfenac sodium Form I is also provided by the present invention. In this method, bromfenac sodium Form III is crystallized or recrystallized from a solvent mixture containing at least one non-solvent such as water, at least one dialkoxyalkane and dialkyl ether, Producing an intermediate product comprising less than 1.5 moles of water per mole of sodium hydroxide and hydrating the intermediate product. Suitable dialkoxyalkanes, dialkyl ethers,
And the hydration conditions are generally similar to the dialkoxyalkanes, dialkyl ethers and hydration conditions described above in connection with the preparation of bromfenac sodium Form I from bromfenac sodium.

The bromfenac sodium polymorph provided by the present invention is useful as an active ingredient in pharmaceutical formulations employed in the treatment of various diseases or conditions, especially inflammatory diseases. The polymorph may be an individual, substantially pure polymorph (ie, substantially free of other physical forms of bromfenac sodium), or two or more different bromfenac sodium polymorphs It may be used as a mixture of The medical uses of bromfenac sodium and similar benzoylphenyl acetates are well known in the art and are described in U.S. Pat. Nos. 4,045,576, 4126635, 4182774, 4683242.
No. and No. 4910225, etc. (the contents of each publication are all included in this specification for reference). The bromfenac sodium polymorph according to the present invention can be used as a carrier, solvent, preservative, stabilizer, surfactant, pH adjuster, dilution, as desired or required for the end use purpose. It may be formulated together with one or more additives such as an agent and a filler. The pharmaceutical formulation may be in solid or liquid form such as tablets, capsules, solutions, suspensions, ointments and the like.

For example, the bromfenac sodium polymorph of the present invention is used as an active ingredient in a locally administered therapeutic composition for inflammatory eye diseases and nasal or ear diseases.

Ophthalmic compositions are manufactured (formulated) in the form of eye drops, eye ointments, etc. in a manner similar to various known compositions for topical administration to the eye. Accordingly, the bromfenac sodium polymorph, or bromfenac sodium polymorph mixture, according to the present invention is manufactured in an aqueous or non-aqueous solution or mixed with an ointment base suitable for ophthalmic use. An aqueous base commonly used in the manufacture of eye drops, such as sterile distilled water, may be suitably used as the aqueous base. If necessary, the pH of the eye drop is adjusted to a level suitable for topical administration to the eye. In one embodiment, a suitable buffer material is added in adjusting the pH. P of eye drops
H should be selected, among other things, with due consideration given to the stability and local eye irritation of the bromfenac sodium active ingredient. In one embodiment, the stability of the aqueous composition comprising bromfenac sodium includes a water soluble polymer and sulfite and pH
6.0-9.0. Desirably, it is improved by adjusting to about 7.5-8.5. Illustrative suitable water soluble polymers include polyvinyl pyrrolidone, carboxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, polyacrylic acid sodium salt, and the like. The water soluble polymer concentration may range from about 0.1 w / w% to about 10 w / w% based on the total weight of the solution. Suitable sulfites include sodium sulfite, potassium sulfite and the like having a sulfite concentration, usually ranging from about 0.1 w / w% to about 1.0 w / w%, based on the total weight of the solution. The pH adjustment is usually performed together with sodium hydroxide, hydrochloric acid, or the like, and the buffer solution may be produced by using sodium acetate, sodium borate or sodium phosphate and acetic acid, boric acid or phosphoric acid in combination. The ophthalmic composition may contain one or more additional active pharmaceutical ingredients such as another type of anti-inflammatory agent, analgesic agent, antibacterial agent, and the like.

In the production of such ophthalmic compositions, one or more isotonic agents, bactericides or preservatives, chelating agents, thickeners, etc. may be added to the composition according to the general practice of eye drop production. Suitable tonicity agents include sorbitol, glycerin, polyethylene glycol, propylene glycol, glucose and sodium chloride, among others. Illustrative preservatives include para-oxybenzoic acid esters, benzyl alcohol, parachloro-metaxylenol, chlorocresol, phenethyl alcohol, sorbic acid, and salts thereof, thimerosal, chlorobutanol, and the like. The chelating agent may be, for example, sodium edetate, sodium citrate, or a sodium salt of condensed phosphoric acid. In the production of an ophthalmic composition in the form of an eye ointment, the ointment base is selected from petrolatum, polyethylene glycol, sodium carboxymethylcellulose and the like.

An ophthalmic composition may be prepared by including bromfenac sodium polymorph, or a mixture of polymorphs, in a base or excipient for topical administration to the eye. In order to produce a liquid formulation, the concentration of the active ingredient may range from about 0.001% to about 10% by weight,
Desirably, it ranges from about 0.01% to about 5% by weight. Ointment is about 0.001% by weight
It may be prepared by using bromfenac sodium polymorph or polymorph mixture at a concentration of ˜about 10%, desirably about 0.01% to about 5% by weight. The ophthalmic composition may be administered, for example, according to any of the following schedules. In the form of eye drops,
One to several drops per dose are infused as often as 1 to 4 times a day, depending on clinical symptoms. This dosage may be adjusted according to the symptoms.

2-Amino-3- (4-bromobenzoyl) phenylacetic acid sodium salt Form II
Production of polymorph I (bromfenac sodium form III)

The solvents used for this reaction (toluene and ethanol) were degassed by bubbling nitrogen gas before use. 7- (4-Bromobenzoyl) indol-2-one solution (Walsh, DA, Moran, HW, Samlee, DA, Uway)
dah, I.D. M.M. Welstead, Jr. , W. J. et al. Sancilio, L .; F.
Dannburg, W .; N. J. et al. Med. Chem. 1984, 27, 1379-
221 g, 0.7 mol) prepared by 1388 was degassed ethanol (0.
4Kg) and degassed toluene (1.4Kg) and was further degassed by bubbling nitrogen gas. A solution of sodium hydroxide in water (65 g) (64 g,
1.61 mol) is produced, degassed by bubbling nitrogen gas, and in part,
To the stirred 7- (4-bromobenzoyl) indol-2-one solution was added. The resulting mixture was further degassed and maintained in a nitrogen gas atmosphere for 15 hours, 68 hours.
Heated to from -72C.

The mixture was then cooled to 28 ° C. and tert-butyl methyl ether (1.7 Kg).
) Was added and after stirring for 2 hours, the solid was filtered. The filtered product is te
Washed with rt-butyl methyl ether (3 × 0.4 Kg) and dried on the filter at ambient temperature under vacuum filtration conditions for 3 hours as 2-amino-3-
The sodium salt Form III polymorph of (4-bromobenzoyl) phenylacetic acid (284 g) was produced and shown by XRPD analysis.

2-amino-3- (4-bromobenzoyl) phenylacetic acid sodium salt Form I
Manufacture of polymorphs (convert Form III polymorph to Form I polymorph)

Sodium salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid, Form II
A 284 g portion of the I polymorph (prepared according to Example 1) is placed in a chemical reactor and a mixture of water (208 g) and 1,2-dimethoxyethane (1.0 Kg) is added. It was. The stirred suspension is degassed by bubbling nitrogen gas and then for 30 minutes.
Heated at 65-71 ° C. The resulting mixture is allowed to settle for 10 minutes,
And after the removal of the low aqueous layer, the organic layer was cooled to 67 ° C. and filtered. This solution is 36
Concentrated to a wet slurry in a vacuum at 0C. To the wet slurry was added tert-butyl methyl ether (1.0 Kg) and the mixture was stirred for 1 hour. The resulting crystalline product was filtered and tert-butyl methyl ether (3 × 0
. 4Kg) and dried on the filter under vacuum filtration conditions for 3 hours and sodium 2-amino-3- (4-bromobenzoyl) phenylacetic acid, sesquihydrate as a yellow solid A salt (243 g) Form I polymorph was produced and shown by XRPD analysis.

2-amino-3- (4-bromobenzoyl) phenylacetic acid sodium salt Form I
Recrystallization of polymorphs

A sodium salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid sesquihydrate, Form I polymorph, 242 g portion was placed in a chemical reactor and water (262
A mixture of g) and 1,2 dimethoxyethane (2.1 Kg) was added. The stirred suspension was degassed by bubbling nitrogen gas and then heated to 65 ° C. to 70 ° C. for 10 minutes or until a solution was obtained. The resulting solution was cooled to 68 ° C. and filtered in a coated conduit maintained at 60 ± 5 ° C. While maintaining the temperature at 60 ± 5 ° C., 1,2-dimethoxyethane (0,0) in tert-butyl methyl ether (1.3 Kg).
. 4 kg) of solution was produced and filled. The stirred mixture was then cooled to 10 ° C. over about 6 hours and maintained at 6 ° C. to 10 ° C. for 1 hour. The resulting crystalline product was filtered and tert-butyl methyl ether (2 × 0.8 Kg)
And dried on the filter under vacuum filtration conditions at ambient temperature for 1 hour,
As a yellow solid with 99.95% chemical purity by HPLC, 2-amino-3- (
Form I polymorph of 4-bromobenzoyl) phenylacetic acid, sodium salt of sesquihydrate (148 g) was produced and was shown by XRPD analysis.

[2-Amino-3- (4-bromobenzoyl) phenylacetic acid, sodium salt of sesquihydrate, Form I polymorph analysis data]
¹ H-NMR (300 MHz, DMSO-d ₆ ) δ (ppm) 3.26 (2H, s),
6.46 (1H, dd, J = 7.9 Hz and 7.3 Hz), 7.08 (1H, dd, J =
8.1 Hz and 1.3 Hz), 7.15 (1H, d, J = 7.1 Hz), 7.49 (2H
, D, J = 8.7 Hz) 7.71 (2H, d, J = 8.7 Hz), 7.96 (2H, bs)
, Exchanged with D ₂ O). ¹³ C-NMR (300 MHz, DMSO-d ₆ ) δ (ppm) 19
7.0, 174.2, 151.7, 139.4, 135.2, 131.4, 131.1,
130.6, 126.5, 124.4, 116.7, 114.0 and 44.9. C ₁₅ H
₁₁ BrNO ₃ ^- carboxylate ion to HRMS be calculated (ES), 331.
9922 [M] ⁺ and 333.9902 [M] ⁺ , discovered 331.9907 [M] ⁺ and 3
33.9893 [M] ⁺ . FT-IR (KBr) 3538, 3416, 3323, 3250
-2900 (br), 1618, 1567, 1437, 1416, 1391, 1319,
1244, 1172, 1067, 1013, 971, 920, 840, 802 and 752
cm ⁻¹ . C ₁₅ H ₁₁ BrNO ₃ Na. The analysis calculated for 1.5H ₂ O is C,
47.02; H, 3.68; N, 3.66; Br, 20.85. Found: C, 47.
13; H, 3.62; N, 3.80; Br, 20.35. The water content by Karl Fischer titration calculated for sesquihydrate was 7.05%. Discovered, 7.
2%. About 4.4, 8.8, 9.4, 12.1, 15.2, 15.9, 17.6, 18.2
, 18.8, 20.2, 21.2, 24.7, 28.4, and 32.4 °, the XRPD analysis specific peak expressed as 2-θ.

2-amino-3- (4-bromobenzoyl) phenylacetic acid sodium salt Form I
And Form II polymorphs (converting Form I polymorphs to a mixture of Form I and Form II polymorphs)

The sodium salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid sesquihydrate, Form I polymorph (148 g) was dried under vacuum at 29 ° C. (29 in Hg) for 6 hours, and then 12 hours under vacuum of 30 ° C. to 32 ° C. (1.2 mmHg to 1.6 mm
Hg) Dried to yield a mixture of (143 g) Form I and Form II polymorphs of the sodium salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid as a yellow solid, shown by XRPD analysis .

表Ｄ．

FIG. 5 shows an XRPD pattern of a representative sample of a mixture of Form I and Form II polymorphs of bromfenac sodium. Characteristic d-spacing /
The% intensity pattern is listed in Table C. (Only peaks with a relative intensity of> 2.0% are listed.) FIG. 6 shows the estimated X for bromfenac sodium form II
An RPD pattern is shown. Table D shows the characteristic d-spacing /% attributed to bromfenac sodium Form II in such a mixture (ie, the major peak due to Form II polymorph).
Describe the intensity pattern.
Table C.

Table D.

Conversion of a mixture of Form I and Form II to Form I polymorph (hydration reaction in a glove bag)

Sodium salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid, Form I
And a tray containing a 117.0 g portion of the polymorphic mixture of II and II was placed in parallel with the tray containing the water in the glove bag. The bag is sealed under nitrogen and the product is allowed to moisten at ambient temperature for 5 hours and as a yellow solid, 2-amino-3-
(4-Bromobenzoyl) phenylacetic acid, sodium salt of sesquihydrate (117.3 g)
Of substantially pure Form I polymorph, which was shown by XRPD analysis.

  Process for the production of Form I polymorph (drying / hydration reaction using wet nitrogen bleed)

10% v / v water of 1,2-dimethoxyethane in tert-butyl methyl ether-1
2-amino-3- (4) obtained after recrystallization from 2-dimethoxyethane-20% v / v
-Bromobenzoyl) phenylacetic acid sodium salt (5 g) was dried in a low moist nitrogen gas bleed for 5 hours under vacuum (29 in Hg) at 30-33 ° C. to give 2- A form I polymorph of amino-3- (4-bromobenzoyl) phenylacetic acid, sodium salt of sesquihydrate (4.4 g) was produced and was shown by XRPD analysis. These conditions have been found to be effective in removing residual organic solvent from bromfenac sodium while ensuring that sesquihydrates are obtained. (That is, the water content is not reduced below 1.5 moles of water per mole of bromfenac sodium.)

Production of a mixture of Form I and Form II polymorphs (hydration reaction using wet nitrogen bleed)

10% v / v water of 1,2-dimethoxyethane in tert-butyl methyl ether-2
2-amino-3- (4-) obtained after recrystallization from 0% v / v 1,2-dimethoxyethane.
Bromobenzoyl) phenylacetic acid sodium salt (26.6 g) for 4 hours at 30 ° C.-3
Under vacuum at 5 ° C. and then with low wet nitrogen gas bleed for 10 hours, 31 ° C.-33
Dry under high vacuum at 30 ° C. (30-50 mm Hg) and as a yellow solid, 2-amino-3- (4-bromobenzoyl) phenylacetic acid, sodium salt of sesquihydrate (26.2 g
) Of Form I and Form II polymorphs were produced and shown by XRPD analysis.
In contrast to Example 6, these drying conditions were effective in removing enough water to form bromfenac sodium Form II, which appears to be the monohydrate of bromfenactrium. there were.

Stability of Form I polymorph 2-amino-3- (4-bromobenzoyl) phenylacetic acid sodium salt, Form I
The polymorph (0.6 g) was placed in a drying dish parallel to the dish containing water (20 g) in a plastic bag. The bag was sealed under nitrogen and the product was allowed to damp for 19 hours. XRPD and water content analysis of the product (0.6 g) showed no change in the polymorph foam.

Conversion of Form I and Form II polymorphs to Form III polymorphs Sodium salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid, Form I
/ Form II polymorph mixture (10 g) with 5% v / v aqueous 2-propanol (100 mL
) And the stirred mixture was heated and maintained at 60-70 ° C. under nitrogen for 1 hour. The mixture was cooled to room temperature and stirred for 1 hour. The resulting thick slurry was filtered, washed with 2-propanol (2 × 10 mL) and dried under vacuum (30 mm-40 ° C.) (1.5 mm Hg) for 16 hours to yield 2 as a yellow solid. -Amino-3- (4-bromobenzoyl) phenylacetic acid, non-hydrate, sodium salt, (9 g) of Form III polymorph was produced and shown by XRPD analysis.
[Analytical data of 2-amino-3- (4-bromobenzoyl) phenylacetic acid, non-hydrate, sodium salt, Form III polymorph]
¹ H-NMR (300 MHz, DMSO-d ₆ ) δ (ppm) 3.29 (2H, s),
6.47 (1H, t, J = 7.6 Hz), 7.09 (1H, dd, J = 8.1 Hz and 1
. 1 Hz), 7.17 (1H, d, J = 7.1 Hz), 7.49 (2H, d, J = 8.3)
Hz), 7.70 (2H, d, J = 8.7 Hz), 7.89 (exchanged for 2H, bs, D ₂ O). ¹³ C-NMR (300 MHz, DMSO-d ₆ ) δ (ppm) 197.0, 174
. 2, 151.7, 139.4, 135.2, 131.4, 131.1, 130.6, 1
26.5, 124.4, 116.7, 114.0 and 44.9. LCMS m / z 334.1 and 332.1 [M] ⁺ , 290.1, 288.1 (C
Loss of O ₂ ). FT-IR (KBr) 3437, 3327, 3048, 2921, 162
3, 1547, 1432, 1411, 1322, 1280, 1237, 1179, 106
0, 1005, 963, 938, 840, 823, 798 and 760 cm ⁻¹ . C ₁₅ H
Analyzes calculated for ₁₁ BrNO ₃ Na were C, 50.59; H, 3.11; N, 3
. 93; Br, 22.44. Discovery: C, 50.62; H, 3.06; N, 3.93; Br
22.19. The water content by Karl Fischer titration was found, 0.56%.
About 12.2, 12.4, 14.1, 15.5, 16.3, 17.8, 18.3, 19.6
21.6, 22.4, 24.0, 26.3, 26.7, 26.8, 27.2, 28.1
, 28.5, 29.7, 30.7, 31.0, 31.7, 34.9, 35.7, 36.2
, 38.3, 38.7, 39.4, 43.4, 46.9, 47.8 and 49.0 °
XRPD analysis specific peak expressed as θ.

Claims (25)

1 6.5, 18.5, 20.7, 34.1, 11.3, 14.4, 17.3, 19.4, 21.0, 22.7, 29.0, 31.8, and Bromofenac sodium containing less than 1.5 moles of water per mole of bromfenac sodium , characterized by a powder X-ray diffraction pattern having a major peak expressed as 2-θ at 36.1 °.   A method for producing a pharmaceutical preparation comprising preparing bromfenac sodium according to claim 1 and at least one additive to prepare a pharmaceutical preparation. A pharmaceutical formulation comprising bromfenac sodium according to claim 1 and at least one additive. The pharmaceutical preparation according to claim 3, which is a pharmaceutical preparation for reducing inflammation of the eye , wherein the pharmaceutical preparation is an ophthalmic composition. A pharmaceutical formulation according to claim 3, wherein the pharmaceutical formulation does not contain an impurity is bromfenac sodium degradation products in AUC0.15% or more of any steps, pharmaceutical formulation. A pharmaceutical formulation according to claim 3, wherein the pharmaceutical formulation comprises 100ppm or less aluminum, boron, and manganese, and the following 30ppm of each of these elements in the entire pharmaceutical preparation. A vial comprising the pharmaceutical formulation of claim 3 . The table below:

The bromfenac sodium according to claim 1, characterized by the XRPD d-interval /% intensity pattern according to 3. The method of claim 2 , wherein the pharmaceutical formulation is a liquid. 10. A method according to claim 9 , wherein the liquid is a solution. 10. The method according to claim 9 , wherein at least one additive is a water soluble polymer. The method according to claim 9, comprising the crystalline form Gab ROM Fe diclofenac sodium Form II of bromfenac sodium, method. 10. The method of claim 9 , wherein the formulation has a pH of 7 . The method, which is 5 to 8.5. 3. A method according to claim 2 , wherein the pharmaceutical formulation is a suspension. 11. The method of claim 10 , wherein the formulated crystalline form of bromfenac sodium is 0 . Dissolved in solution in an amount of from 01% to 5 % by weight. 10. The method according to claim 9 , wherein the at least one additive is selected from the group consisting of a carrier, a solvent, a preservative, a stabilizer, a surfactant, a pH adjuster, a diluent, and a filler. The method according to claim 2 , wherein at least one additive comprises a preservative, a chelating agent, a pH adjuster, a water-soluble polymer, a sulfite, a buffer material, and water. 3. The method according to claim 2 , wherein the pH adjuster comprises sodium hydroxide, the water-soluble polymer comprises polyvinyl pyrrolidone, the sulfite comprises sodium sulfite, and the buffer material comprises boric acid and sodium borate. ,Method. The method of claim 18 , wherein the chelating agent comprises sodium edetate. A pharmaceutical formulation according to claim 4, wherein the ophthalmic composition is an eye drop, the pharmaceutical formulation. A pharmaceutical formulation according to claim 4, wherein the inflammation is a result of a surgical procedure or surgery, pharmaceutical formulation. A pharmaceutical preparation for the relief of eye pain, the pharmaceutical preparation is an ophthalmic composition, pharmaceutical formulation of claim 3. A pharmaceutical formulation according to claim 22, wherein the ophthalmic composition is an eye drop, the pharmaceutical formulation. A pharmaceutical formulation according to claim 22, pain of the inflammation is a result of surgery, a pharmaceutical formulation. A pharmaceutical formulation according to claim 24, wherein the surgery is cataract surgery or refractive surgery, a pharmaceutical formulation.

Images